Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/171689
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCasanovas i Casanovas, Oriol-
dc.date.accessioned2020-11-02T09:44:09Z-
dc.date.available2020-11-02T09:44:09Z-
dc.date.issued2012-04-01-
dc.identifier.urihttp://hdl.handle.net/2445/171689-
dc.description.abstractAnti-angiogenic drugs, used for cancer treatment, target blood-vessel formation in tumours. Two studies commented here show that such drugs can reduce the efficiency of other anticancer agents and increase the aggressiveness of tumours.-
dc.format.extent6 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherSpringer Science and Business Media LLC-
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1038/484044a-
dc.relation.ispartofNature, 2012, vol. 484, issue. 7392, p. 44-46-
dc.relation.urihttps://doi.org/10.1038/484044a-
dc.rights(c) Springer Science and Business Media LLC, 2012-
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationAngiogènesi-
dc.subject.classificationMedicaments antineoplàstics-
dc.subject.classificationTumors-
dc.subject.otherNeovascularization-
dc.subject.otherAntineoplastic agents-
dc.titleCancer: Limitations of therapies exposed-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/AcceptedVersion-
dc.date.updated2020-10-29T15:04:25Z-
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/281830/EU//STROMALIGN-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
Casanovas News&Views_v6_POST-PRINT.pdf518.27 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.